The results are based on patients who have already tried Keytruda and had poor outcomes. (see below)
Very happy to see these excellent results. Combo therapy seems to be proving a rewarding process.
Patients having a suboptimal response or having had disease progression with pembrolizumab monotherapy are eligible for the study and will receive the combination of pembrolizumab plus eftilagimod alpha.
https://www.immutep.com/pipeline/clinical-trials.html
Ann: TACTI-mel data presented at World Immunotherapy Congress, page-14
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.3¢ | $884.2K | 2.836M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34624 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 250082 | 6 |
View Market Depth
| Last trade - 16.10pm 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
